ENANTA PHARMACEUTICALS INC (ENTA) — SEC Financial Statements & Analysis

ENANTA PHARMACEUTICALS INC (ENTA) is a pharmaceutical preparations company. ENANTA PHARMACEUTICALS INC trades on Nasdaq as: ENTA. ENANTA PHARMACEUTICALS INC (ENTA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, ENANTA PHARMACEUTICALS INC carries a market cap of $424.13M, a P/E ratio of -6.71x, a P/B ratio of 4.20x, a P/S ratio of 6.50x, an enterprise value of $390.71M, and an EV/EBITDA multiple of -7.26x. On profitability, it posts a gross margin of 115.99%, an operating margin of -89.99%, a net margin of -96.89%, a Return on Equity (ROE) of -70.12%, a Return on Assets (ROA) of -21.15%, and a Return on Invested Capital (ROIC) of -112.16%. Per share, it reports EPS of $-2.17, diluted EPS of $-2.17, free cash flow per share of $-1.27, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 0.70% year-over-year, net income growth of -31.28% year-over-year, and EPS growth of -49.50% year-over-year. On the balance sheet, it maintains a current ratio of 3.76x, a quick ratio of 3.62x, working capital of $149.45M, a debt-to-equity ratio of 1.94x, a debt ratio of 0.66, an interest coverage ratio of -4.55x, free cash flow of $-36.94M (TTM), and net debt of $-33.42M. Figures sourced from SEC EDGAR.

Market Cap

$424.13M

P/E TTM

-6.71x

EPS TTM

$-2.17

P/B TTM

4.20x

ROE TTM

-70.12%

ROA TTM

-21.15%

Debt To Equity

1.94x

Free Cash Flow TTM

$-36.94M

Net Revenue TTM Growth 1Y

0.70%

Data as of 2026-06-30 · Source: SEC EDGAR